Liquidia Shares Rise Over 42% Following Settlement with United Therapeutics
Shares of Liquidia (LQDA) surged more than 42% after the company announced a $380.7 million settlement agreement with United Therapeutics (UTHR), resolving six ongoing legal disputes related to its drug YUTREPIA for pulmonary arterial hypertension. The deal allows Liquidia to continue commercializing YUTREPIA, which is used in treating patients with this condition. As part of the terms, Liquidia will pay $175 million within 30 business days and two additional installments totaling $145.4 million over time. The resolution ends a prolonged legal battle that had created uncertainty around YUTREPIA's market access. The settlement is expected to provide clarity for investors regarding the drug’s future, potentially stabilizing Liquidia’s revenue stream from this key product and reducing litigation-related risks.